Phase I dose escalation study of naive T-cell depleted donor lymphocyte infusion following allogeneic stem cell transplantation.

ABSTRACT: Prophylactic donor lymphocyte infusions (DLI) are used to augment post-transplant immune recovery to reduce both infectious complications and disease recurrence. Preclinical studies implicate the naive T-cell subset as the primary driver of graft-versus-host disease (GvHD). In this phase I dose escalation study, we assessed the safety of a DLI that was depleted of CD45RA+ naive T cells. Sixteen adult patients received a prophylactic DLI at a median of 113 days (range 76-280 days) following an HLA-identical, non-myeloablative allogeneic hematopoietic stem cell transplantation. Three patients each received the naive T-cell depleted DLI with a CD3+ dose of 1 × 10⁵/kg, 1 × 10⁶/kg, and 5 × 10⁶/kg. The maximum dose of 1 × 10⁷/kg was expanded to 7 patie

SUBMITTER: Maung KK 

PROVIDER: S-EPMC10805111 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature